Zentiva is a pharmaceutical company headquartered in Prague, Czech Republic, with roots tracing back over 500 years to a small pharmacy called Black Eagle, which still exists today in the heart of Prague. This long history underpins its current role as a Pan-European platform dedicated to developing, manufacturing, and marketing a wide range of generic, specialty, and consumer healthcare pharmaceutical products.

The company employs nearly 4,800 people and operates 31 subsidiaries and 7 branches across 35 countries, with manufacturing sites in Prague, Bucharest, and Ankleshwar, supported also by a broad network of external manufacturing partners to ensure supply security. Zentiva offers medicines focused on key therapeutic areas including cardiology, diabetes, oncology, respiratory health, and central nervous system disorders, as well as expanding its portfolio in self-care and consumer healthcare.

Since becoming independent in 2018 under the ownership of the private equity firm Advent International, Zentiva has doubled the size of its business and expanded its geographical reach throughout Europe, delivering sustainable double-digit growth. It remains committed to providing high-quality, affordable medicines that contribute significantly to public health, serving over 100 million people across Europe.

Zentiva emphasizes a corporate culture that values diversity and inclusion, aiming to be a great place to work where employees feel welcomed, appreciated, and empowered to contribute fully. The company also highlights its commitment to data protection as an integral part of its operations.

Overall, Zentiva stands as a leading pharmaceutical organization with a deep historical legacy, robust European presence, and a mission dedicated to health and wellbeing through accessible medication.